Clinical trials of monoclonal antibodies in combination with chemotherapy have reported previously unattained response rates in patients with B-cell chronic lymphocytic leukemia (B-CLL); however, the analysis of ZAP-70 protein and/or CD38 may explain better the discordant outcomes independent of treatment.
DEL POETA, G., DEL PRINCIPE, M.i., Consalvo, M., Maurillo, L., Buccisano, F., Venditti, A., et al. (2005). The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. CANCER, 104(12), 2743-2752 [10.1002/cncr.21535].
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia
DEL POETA, GIOVANNI;DEL PRINCIPE, MARIA ILARIA;BUCCISANO, FRANCESCO;VENDITTI, ADRIANO;BRUNO, ANTONIO;LO COCO, FRANCESCO;CANTONETTI, MARIA;AMADORI, SERGIO
2005-12-15
Abstract
Clinical trials of monoclonal antibodies in combination with chemotherapy have reported previously unattained response rates in patients with B-cell chronic lymphocytic leukemia (B-CLL); however, the analysis of ZAP-70 protein and/or CD38 may explain better the discordant outcomes independent of treatment.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.